Cystic fibrosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2165/00019053-200321140-00002PMID 7924914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience.

  2006cited by this paper
• Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience.

  2001cited by this paper
• Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment

  2001cited by this paper
• Changes in strategies for optimal antibacterial therapy in cystic fibrosis.

  2001cited by this paper
• Pharmacological treatment of the biochemical defect in cystic fibrosis airways.

  2001cited by this paper
• Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.

  2000cited by this paper
• Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis

  2000cited by this paper
• DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres

  2000cited by this paper
• Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

  2000cited by this paper
• Cost of Care for Individuals with Cystic Fibrosis: A Regression Approach to Determining the Impact of Recombinant Human DNase

  1999cited by this paper
• Kostenvergleichsanalyse der stationären und ambulanten Intervalltherapie bei erwachsenen Mukoviszidosepatienten

  1999cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.

  1999cited by this paper
• The gender gap in cystic fibrosis survival.

  1999cited by this paper
• Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967

  1999cited by this paper
• Burkholderia cepacia in cystic fibrosis. Variable disease course.

  1999cited by this paper
• The Cost of Medical Care for Patients With Cystic Fibrosis in a Health Maintenance Organization

  1999cited by this paper
• Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report.

  1999cited by this paper
• Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.

  1998cited by this paper
• The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis.

  1998cited by this paper
• Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis

  1998cited by this paper
• Ökonomische Aspekte der Behandlung zystischer Fibrose mit chronischer pulmonaler Pseudomonasinfektion

  1997cited by this paper
• Retrospective review of the effects of rhDNase in children with cystic fibrosis

  1997cited by this paper
• Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.

  1997cited by this paper
• Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.

  1997cited by this paper
• Incidence, population, and survival of cystic fibrosis in the UK, 1968–95

  1997cited by this paper
• Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

  1997cited by this paper
• Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis

  1997cited by this paper
• Avoiding Double-Counting in Pharmacoeconomic Studies

  1997cited by this paper
• Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

  1997cited by this paper
• Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid program, fiscal year 1993.

  1997cited by this paper
• Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1.

  1996cited by this paper
• The nonhospital costs of care of patients with CF in The Netherlands: results of a questionnaire.

  1996cited by this paper
• Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.

  1996cited by this paper
• Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

  1996cited by this paper
• Improved survival in the Danish center‐treated cystic fibrosis patients: Results of aggressive treatment

  1996cited by this paper
• Clinical Investigations: Airways: ArticlesEffects of 12-Week Administration of Dornase Alfa in Patients with Advanced Cystic Fibrosis Lung Disease

  1996cited by this paper
• Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.

  1996cited by this paper
• A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis

  1996cited by this paper
• Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

  1996cited by this paper
• Management of pulmonary disease in patients with cystic fibrosis.

  1996cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis

  1995cited by this paper
• Home care in cystic fibrosis patients.

  1995cited by this paper
• Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis.

  1995cited by this paper
• CFTR as a cAMP-dependent regulator of sodium channels

  1995cited by this paper
• Comment: cost of rhDNase in cystic fibrosis

  1995cited by this paper
• Physicians, pharmacists, and home infusion antibiotic therapy.

  1994cited by this paper
• Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

  1994cited by this paper
• Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.

  1994cited by this paper
• [The mucoviscidosis patient in the transition between childhood and adolescence].

  1994cited by this paper
• High-technology in home care. An overview of intravenous therapy.

  1994cited by this paper
• Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis.

  1994cited by this paper
• [Cystic fibrosis. New clinical, pathogenetic and molecular biological concepts].

  1994cited by this paper
• Antibiotic therapy for chronic infection of pseudomonas in the lung.

  1993cited by this paper
• [Continuous intravenous antibiotic home treatment in 11 patients with cystic fibrosis in The Northern Netherlands].

  1993cited by this paper
• Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis.

  1993cited by this paper
• No added benefit from nebulized amiloride in patients with cystic fibrosis.

  1993cited by this paper
• [Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study].

  1993cited by this paper
• The changing epidemiology of cystic fibrosis.

  1993cited by this paper
• Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

  1993cited by this paper
• Progress toward human gene therapy.

  1993cited by this paper
• A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients.

  1992cited by this paper
• Prediction of mortality in patients with cystic fibrosis.

  1992cited by this paper
• Cystic fibrosis, intravenous antibiotics, and home therapy.

  1991cited by this paper
• Cystic fibrosis: current survival and population estimates to the year 2000.

  1991cited by this paper
• Intravenous antibiotics at home in children with cystic fibrosis.

  1990cited by this paper
• Increasing survival of Swedish patients with CF.

  1990cited by this paper
• Let parents give the care: iv therapy at home in cystic fibrosis.

  1989cited by this paper
• Home intravenous antibiotic treatment in cystic fibrosis.

  1988cited by this paper
• Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients

  1988cited by this paper
• A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.

  1988cited by this paper
• Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease.

  1987cited by this paper
• Feasibility and Cost Savings of Intravenous Administration of Aminoglycosides in Outpatients with Cystic Fibrosis

  1985cited by this paper
• Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis.

  1984cited by this paper
• Self-administration of intravenous antibiotics: an efficient, cost-effective home care program.

  1982cited by this paper
• Outpatient intravenous medications in the management of cystic fibrosis.

  1974cited by this paper
• The role of the clinical specialist in surgical nursing.

  1968cited by this paper
• The Subdivisions of Chronic Metritis

  1914cited by this paper

• Evaluation of Quality of Life in Patients with Cystic Fibrosis Regarding Smoking History in Parents

  2022cites this paper
• Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe

  2022cites this paper
• Retracing changes in cystic fibrosis understanding and management over the past twenty years.

  2021cites this paper
• The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective

  2019cites this paper
• Immunopathology of Airway Surface Liquid Dehydration Disease

  2019cites this paper
• Costs of treatment of adult patients with cystic fibrosis in Poland and internationally.

  2017cites this paper
• The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy

  2017cites this paper
• A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis

  2016cites this paper
• Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data

  2015cites this paper
• Preventable spina bifida and anencephaly in Europe.

  2015cites this paper
• [Cystic fibrosis -- disease burden and health-related quality of life of patients and their caregivers: results of the European BURQOL-RD survey in Hungary].

  2014cites this paper
• Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

  2014cites this paper
• Program of home telemonitoring in patients with cystic fibrosis over a period of 2 years: a contribution to the rationalization of care.

  2013cites this paper
• Original article Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

  2013cites this paper
• Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.

  2012cites this paper
• Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.

  2012cites this paper
• Hospitalisation Costs of Cystic Fibrosis

  2012cites this paper
• Importance du stress oxydant dans le diabète secondaire à la fibrose kystique

  2010cites this paper
• The Economics of Cystic Fibrosis care in the East of England

  2010cites this paper
• Medikamentöse Behandlung von Mukoviszidose – Kostenstruktur und Einsparpotenzial der ambulanten Behandlung

  2010cites this paper
• The scope of costs in alcohol studies: Cost-of-illness studies differ from economic evaluations

  2010cites this paper
• Outpatient medication costs of patients with cystic fibrosis in Germany

  2010cites this paper